Nautilus Biotechnology to Participate in B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference
23 Março 2023 - 9:00AM
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a
company pioneering a single-molecule protein analysis platform,
today announced the company will be participating in the upcoming
B. Riley Securities’ Disruptive Biotech Enabling Technologies –
Proteomics, Virtual Conference.
Nautilus’ management is scheduled to participate in a fireside
chat on Thursday, April 6th at 10:30 a.m. Pacific Time / 1:30 p.m.
Eastern Time. Interested parties may access a live and archived
webcast of the presentation on the company’s website on the
“Investors” section of the company website at:
www.nautilus.bio.
About Nautilus Biotechnology, Inc.With its
corporate headquarters in Seattle and its research and development
headquarters in the San Francisco Bay Area, Nautilus is a
development stage life sciences company creating a platform
technology for quantifying and unlocking the complexity of the
proteome. Nautilus’ mission is to transform the field of proteomics
by democratizing access to the proteome and enabling fundamental
advancements across human health and medicine. To learn more about
Nautilus, visit www.nautilus.bio.
Media Contactpress@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
Nautilus Biotechnology (NASDAQ:NAUT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Nautilus Biotechnology (NASDAQ:NAUT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024